Ignite Creation Date:
2025-12-25 @ 3:32 AM
Ignite Modification Date:
2025-12-26 @ 2:14 AM
Study NCT ID:
NCT01709305
Status:
COMPLETED
Last Update Posted:
2018-08-21
First Post:
2012-10-16
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-11-08
Start Date Type:
ACTUAL
Primary Completion Date:
2015-04-17
Primary Completion Date Type:
ACTUAL
Completion Date:
2015-04-17
Completion Date Type:
ACTUAL
First Submit Date:
2012-10-16
First Submit QC Date:
None
Study First Post Date:
2012-10-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-04-06
Results First Submit QC Date:
None
Results First Post Date:
2016-05-11
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-07-23
Last Update Post Date:
2018-08-21
Last Update Post Date Type:
ACTUAL